Xiang YJ - Search Results

1

Efficacy and safety of TACE combined with lenvatinib and PD-1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study.

Wang WJ, Liu ZH, Wang K, Yu HM, Cheng YQ, Xiang YJ, Feng JK, Zhou LP, Zhou HK, Pan WW, Guo WX, Shi J, Cheng SQ. Wang WJ, et al. Among authors: xiang yj. Cancer Med. 2023 May;12(10):11513-11524. doi: 10.1002/cam4.5880. Epub 2023 Mar 31. Cancer Med. 2023. PMID: 36999793 Free PMC article.

2

Prognostic Value of Microvascular Invasion in Eight Existing Staging Systems for Hepatocellular Carcinoma: A Bi-Centeric Retrospective Cohort Study.

Xiang YJ, Wang K, Zheng YT, Yu HM, Cheng YQ, Wang WJ, Shan YF, Cheng SQ. Xiang YJ, et al. Front Oncol. 2021 Dec 16;11:726569. doi: 10.3389/fonc.2021.726569. eCollection 2021. Front Oncol. 2021. PMID: 34976789 Free PMC article.

3

A novel classification in predicting prognosis and guiding postoperative management after R0 liver resection for patients with hepatocellular carcinoma and microvascular invasion.

Wang K, Xiang YJ, Yu HM, Cheng YQ, Qin YY, Wang WJ, Zhang XP, Zheng YT, Shan YF, Cong WM, Dong H, Lau WY, Cheng SQ. Wang K, et al. Among authors: xiang yj. Eur J Surg Oncol. 2022 Jun;48(6):1348-1355. doi: 10.1016/j.ejso.2021.12.466. Epub 2021 Dec 29. Eur J Surg Oncol. 2022. PMID: 34996665

4

Effects of Stereotactic Body Radiation Therapy Plus PD-1 Inhibitors for Patients With Transarterial Chemoembolization Refractory.

Xiang YJ, Wang K, Zheng YT, Feng S, Yu HM, Li XW, Cheng X, Cheng YQ, Feng JK, Zhou LP, Meng Y, Zhai J, Shan YF, Cheng SQ. Xiang YJ, et al. Front Oncol. 2022 Mar 21;12:839605. doi: 10.3389/fonc.2022.839605. eCollection 2022. Front Oncol. 2022. PMID: 35387113 Free PMC article.

5

Recurrence hazard rate in patients with hepatocellular carcinoma and bile duct tumor thrombus: a multicenter observational study.

Xiang YJ, Sun JX, Wu JY, Wang K, Feng JK, Wei YG, Zhou JY, Zhang ZB, Zhang YQ, Qin YY, Yan ML, Cheng SQ. Xiang YJ, et al. HPB (Oxford). 2022 Oct;24(10):1703-1710. doi: 10.1016/j.hpb.2022.04.007. Epub 2022 Apr 22. HPB (Oxford). 2022. PMID: 35523655 Free article.

6

Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib for intermediate-stage hepatocellular carcinoma.

Xiang YJ, Wang K, Yu HM, Li XW, Cheng YQ, Wang WJ, Feng JK, Bo MH, Qin YY, Zheng YT, Shan YF, Zhou LP, Zhai J, Cheng SQ. Xiang YJ, et al. Hepatol Res. 2022 Aug;52(8):721-729. doi: 10.1111/hepr.13773. Epub 2022 May 22. Hepatol Res. 2022. PMID: 35536197

7

Perioperative and long-term survival outcomes of laparoscopic versus laparotomic hepatectomy for BCLC stages 0-A hepatocellular carcinoma patients associated with or without microvascular invasion: a multicenter, propensity score matching analysis.

Yang SY, Yan ML, Duan YF, Feng JK, Ye JZ, Xiang YJ, Liu ZH, Guo L, Xue J, Cheng SQ, Guo WX. Yang SY, et al. Among authors: xiang yj. Hepatol Int. 2022 Aug;16(4):892-905. doi: 10.1007/s12072-022-10353-4. Epub 2022 Jun 15. Hepatol Int. 2022. PMID: 35704267

8

Hazard rate for postoperative recurrence in patients with hepatocellular carcinoma at Barcelona Clinic Liver Cancer stage 0 or A1: A multicenter observational study.

Xiang YJ, Wang K, Yu HM, Wang MM, Li LQ, Sun HC, Wen TF, Zhang YQ, Shan YF, Zhou LP, Cheng SQ. Xiang YJ, et al. Hepatol Res. 2022 Nov;52(11):947-956. doi: 10.1111/hepr.13811. Epub 2022 Aug 16. Hepatol Res. 2022. PMID: 35839151

9

Transcatheter arterial chemoembolization plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: a single-arm, phase II trial.

Wang K, Yu HM, Xiang YJ, Cheng YQ, Ni QZ, Guo WX, Shi J, Feng S, Zhai J, Cheng SQ. Wang K, et al. Among authors: xiang yj. Future Oncol. 2022 Sep;18(30):3367-3375. doi: 10.2217/fon-2022-0188. Epub 2022 Aug 15. Future Oncol. 2022. PMID: 35968836

10

A deep learning model with incorporation of microvascular invasion area as a factor in predicting prognosis of hepatocellular carcinoma after R0 hepatectomy.

Wang K, Xiang Y, Yan J, Zhu Y, Chen H, Yu H, Cheng Y, Li X, Dong W, Ji Y, Li J, Xie D, Lau WY, Yao J, Cheng S. Wang K, et al. Hepatol Int. 2022 Oct;16(5):1188-1198. doi: 10.1007/s12072-022-10393-w. Epub 2022 Aug 24. Hepatol Int. 2022. PMID: 36001229

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

68 results

Search Page